| 1 |
35290929 | Exploration of novel VEGFR2 tyrosine kinase inhibitors via design and synthesis of new alkylated indolyl-triazole Schiff bases for targeting breast cancer. | 2022 May |
1 |
| 2 |
35313079 | CRISPR-mediated knockout of VEGFR2/KDR inhibits cell growth in a squamous thyroid cancer cell line. | 2022 May |
1 |
| 3 |
35562342 | DMDRMR promotes angiogenesis via antagonizing DAB2IP in clear cell renal cell carcinoma. | 2022 May 13 |
1 |
| 4 |
33078449 | Synthesis, biological evaluation, and in silico study of pyrazoline-conjugated 2,4-dimethyl-1H-pyrrole-3-carboxylic acid derivatives. | 2021 Feb |
1 |
| 5 |
33170322 | An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib. | 2021 Jan |
2 |
| 6 |
33309571 | Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis. | 2021 Jan |
1 |
| 7 |
33455080 | Dysregulation of the Sirt5/IDH2 axis contributes to sunitinib resistance in human renal cancer cells. | 2021 Mar |
4 |
| 8 |
33647840 | Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer. | 2021 Apr 1 |
1 |
| 9 |
34243074 | 3-Alkenyl-2-oxindoles: Synthesis, antiproliferative and antiviral properties against SARS-CoV-2. | 2021 Sep |
1 |
| 10 |
34306023 | Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. | 2021 |
2 |
| 11 |
34853223 | Vascular Endothelial Growth Factor Receptor Inhibitors Impair Left Ventricular Diastolic Functions. | 2021 |
1 |
| 12 |
34912710 | Identification of a Novel Stem Cell Subtype for Clear Cell Renal Cell Carcinoma Based on Stem Cell Gene Profiling. | 2021 |
2 |
| 13 |
32767163 | Treating metastatic clear-cell renal cell carcinoma: beyond immunotherapy. | 2020 Aug 7 |
1 |
| 14 |
32885522 | Structure-activity relationship studies of indolin-2-one derivatives as vascular endothelial growth factor receptor inhibitors and anticancer agents. | 2020 Dec |
1 |
| 15 |
32923192 | Sunitinib: An Unusual Cause of Pneumothorax in a Patient With Metastatic Chromophobe Renal Cell Carcinoma. | 2020 Aug 6 |
2 |
| 16 |
32947227 | Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity. | 2020 Dec 15 |
4 |
| 17 |
33038552 | Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity. | 2020 Dec |
1 |
| 18 |
30401688 | Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. | 2019 Feb 15 |
2 |
| 19 |
30566287 | Synthesis, Characterization and in vitro Studies of a Cathepsin B-Cleavable Prodrug of the VEGFR Inhibitor Sunitinib. | 2019 Jan |
2 |
| 20 |
30689282 | Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation. | 2019 May |
3 |
| 21 |
30914797 | The adjuvant treatment of kidney cancer: a multidisciplinary outlook. | 2019 Jul |
2 |
| 22 |
31054432 | Exploration of N-alkyl-2-[(4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydroquinazolin-2-yl)thio]acetamide derivatives as anticancer and radiosensitizing agents. | 2019 Jul |
1 |
| 23 |
31231785 | Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer. | 2019 Dec |
2 |
| 24 |
31297023 | Synthesis, anticancer, apoptosis-inducing activities and EGFR and VEGFR2 assay mechanistic studies of 5,5-diphenylimidazolidine-2,4-dione derivatives: Molecular docking studies. | 2019 Jul |
1 |
| 25 |
29095068 | Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. | 2018 Apr |
5 |
| 26 |
29289530 | A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs. | 2018 Jan |
1 |
| 27 |
29554654 | Radiotherapy and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors in Renal Cancer. | 2018 Mar 19 |
1 |
| 28 |
29662541 | Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. | 2018 Mar |
3 |
| 29 |
27030134 | Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma. | 2017 Feb |
3 |
| 30 |
28123542 | Influence of VEGFR single nucleotide polymorphisms on the efficacy of sunitinib therapy against renal cell carcinoma. | 2017 Jan |
4 |
| 31 |
28276433 | Renal cell carcinoma. | 2017 Mar 9 |
1 |
| 32 |
28423517 | Next generation sequencing of extraskeletal myxoid chondrosarcoma. | 2017 Mar 28 |
1 |
| 33 |
28430711 | Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma. | 2017 Jun |
2 |
| 34 |
28561780 | Synthesis and Evaluation of Novel 2-Pyrrolidone-Fused (2-Oxoindolin-3-ylidene)methylpyrrole Derivatives as Potential Multi-Target Tyrosine Kinase Receptor Inhibitors. | 2017 May 31 |
2 |
| 35 |
28954991 | Antiangiogenic agent sunitinib induces epithelial to mesenchymal transition and accelerates motility of colorectal cancer cells. | 2017 |
3 |
| 36 |
28978162 | Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis. | 2017 Sep 15 |
3 |
| 37 |
29086859 | Structural optimization and evaluation of novel 2-pyrrolidone-fused (2-oxoindolin-3-ylidene)methylpyrrole derivatives as potential VEGFR-2/PDGFRβ inhibitors. | 2017 Aug 1 |
1 |
| 38 |
26439451 | Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. | 2016 Jan 1 |
2 |
| 39 |
26597115 | Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells. | 2016 Sep |
2 |
| 40 |
27103123 | Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma. | 2016 Jun |
2 |
| 41 |
27109549 | Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021. | 2016 Jul |
3 |
| 42 |
27149458 | Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report. | 2016 May |
1 |
| 43 |
27164264 | Tyrosine kinase inhibitor sunitinib therapy is effective in the treatment of bone metastasis from cancer of unknown primary: Identification of clinical and immunohistochemical biomarkers predicting survival. | 2016 Sep 15 |
1 |
| 44 |
27175586 | Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. | 2016 Jun 21 |
1 |
| 45 |
27288242 | The tyrosine kinase inhibitor, sunitinib malate, induces cognitive impairment in vivo via dysregulating VEGFR signaling, apoptotic and autophagic machineries. | 2016 Sep |
2 |
| 46 |
27822356 | Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series. | 2016 |
1 |
| 47 |
30695560 | [Sunitinib: 10 years after approval for the therapy of metastatic renal cell carcinoma]. | 2016 |
2 |
| 48 |
24710685 | Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma. | 2015 Jan |
2 |
| 49 |
25100872 | Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. | 2015 Jan |
4 |
| 50 |
25422908 | Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma. | 2015 Jan 6 |
1 |